Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Astellas Pharma keeps profit forecast as prostate cancer drug sales rise

share with twitter share with LinkedIn share with facebook
share via e-mail
01/31/2020 | 03:29am EDT
FILE PHOTO: Astellas Pharma's logo is pictured at its headquarters in Tokyo

Japan's Astellas Pharma Inc reiterated its full-year operating profit forecast on Friday, as a jump in sales of its prostate cancer drug Xtandi countered overseas acquisition costs.

The company said it expects an operating profit of 263 billion yen ($2.4 billion) for the year ending March 31, higher than analysts' average expectation of 256 billion yen, according to IBES data from Refinitiv. Astellas reported an annual operating profit of 244 billion yen last year.

Shares in the company closed 2.4% higher in Tokyo compared with a 1% rise in the broader market.

Sales of Xtandi rose 18% to 298 billion yen in the third quarter ended Dec. 31.

However, core operating profit for the quarter was 3.3% lower, hurt partly by a 2.5% drop in revenue from Prograf, used to prevent rejection of organ transplants.

The company also said it will book a one-off charge of about $100 million in the fourth quarter related to its purchase of U.S.-based biotech Audentes Therapeutics Inc.

Astellas, the country's second-biggest drugmaker by sales, has ramped up overseas acquisitions to broaden its drug pipeline.

The company said in December it would pay up to $665 billion for Xyphos Biosciences Inc to expand its immuno-oncology business. Earlier that month, Astellas said it would purchase Audentes in a deal worth $2.65 billion to expand into genetic medicines.

Both Xyphos and Audentes are based in San Francisco, a hub for biotech companies that are fetching huge premiums for global pharma firms eager to bolster their drug pipelines.

Among other major Japanese pharma companies reporting earnings, Daiichi Sankyo Co, Japan's fourth-largest drug company by sales, raised its full-year operating profit forecast, citing lower taxes. It expects to earn 135 billion yen in the year ending March 31 versus 125 billion predicted in October.

Eisai Co, the partner of Biogen Inc on Alzheimer's disease drug candidate aducanumab, maintained its full-year operating profit forecast at 110 billion yen, a 16% increase from last year, driven by sales of its cancer drug Lenvima.

Daiichi Sankyo shares rose 1.6% while Eisai gained 2.2%.

By Rocky Swift

Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 4.83% 1520 End-of-day quote.2.70%
BIOGEN INC. -2.69% 296.75 Delayed Quote.0.01%
DAIICHI SANKYO COMPANY, LIMITED -1.50% 6611 End-of-day quote.-4.17%
EISAI CO., LTD. 2.90% 6879 End-of-day quote.0.98%
SANKYO CO., LTD. 3.00% 3095 End-of-day quote.0.16%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTELLAS PHARMA INC.
03/24CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop ..
AQ
03/23ASTELLAS PHARMA : CytomX Therapeutics and Astellas Announce Strategic Collaborat..
PU
03/18ASTELLAS PHARMA : Gifu University and Astellas establish a Research Course on Ph..
AQ
02/27ASTELLAS PHARMA : Notice Regarding the Performance-linked Stock Compensation Sch..
PU
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
AQ
02/19ASTELLAS PHARMA : and Seattle Genetics Receive FDA Breakthrough Therapy Designat..
PU
02/12ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..
AQ
02/11SEATTLE GENETICS : and Astellas Announce Updated Results from Phase 1b/2 Trial o..
AQ
02/06ASTELLAS PHARMA : Announces Management Structure
AQ
02/03ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancell..
PU
More news
Financials (JPY)
Sales 2020 1 275 B
EBIT 2020 257 B
Net income 2020 204 B
Finance 2020 458 B
Yield 2020 2,37%
P/E ratio 2020 15,3x
P/E ratio 2021 15,3x
EV / Sales2020 2,15x
EV / Sales2021 2,06x
Capitalization 3 205 B
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 129,17  JPY
Last Close Price 1 724,50  JPY
Spread / Highest target 68,2%
Spread / Average Target 23,5%
Spread / Lowest Target -13,0%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.2.70%29 657
JOHNSON & JOHNSON-13.23%324 693
ROCHE HOLDING AG-5.29%264 026
MERCK & CO., INC-21.13%181 927
NOVARTIS-16.30%180 007
PFIZER, INC.-21.13%171 422